Many patients with early stage non–small-cell lung cancer develop metastases after stereotactic body radiation therapy. We retrospectively analyzed multiple variables in 406 lesions to develop a predictor for metastatic failure. Gross tumor volume and prescription dose were significantly associated with metastases. A metastasis risk score tool was developed to identify patients at higher risk for metastases after lung stereotactic body radiation therapy who might benefit from enrollment in future trials evaluating the benefit of adjuvant or intensified treatment.
- Stereotactic body ablative radiotherapy
- Stereotactic body radiation therapy
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cancer Research